Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

181 through 190 of 311

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Can population-based DNA sequencing find more people at risk for hereditary cancers?

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women over age 30

It is well documented that many BRCA mutation carriers are missed using current family history-based screening approaches. As a result, experts are beginning to call for population-based BRCA genetic testing—an organized effort to screen all women like we do for breast and cervical cancer.  A recent study looked at whether a population-based genetic testing approach would better identify mutation carriers compared with current practice. (11/17/18)

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : The importance of racial diversity in clinical trials

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People who are a member of a racial or ethnic minority group

This article by journalists Caroline Chen and Riley Wong looks at racial disparities between participation in clinical trials and the population of people with cancer. (11/6/18)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Surgeon attitude impacts rate of genetic testing after a breast cancer diagnosis

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Young women diagnosed with breast cancer who have not yet had genetic testing

A study in JAMA Surgery this year examined the factors that impact genetic testing after a breast cancer diagnosis. This study suggests that the attitudes of attending surgeons about genetic testing have the most impact on whether patients receive testing. (10/6/18)

Read More

Relevance: Medium-Low

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : A new method for determining whether genetic variants in BRCA1 increase cancer risk

Relevance: Medium-Low

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People who have a Variant of Uncertain Significance in a gene associated with cancer risk.

Ever since BRCA1 was discovered, researchers have been trying to understand which of the thousands of possible DNA changes in this gene increase cancer risk and which are harmless changes.  A new study in Nature reports how a cutting-edge technology called “genome editing” may be used to classify changes—known as variants of uncertain significance-in BRCA1 as harmful or harmless. Once validated, this same technology may be used to classify variants in other genes. (9/29/18)

Read More

Relevance: Medium-High

Quality of Writing: Medium-High

Article : Cancer experience in families affects decision making

Relevance: Medium-High

Quality of Writing: Medium-High

Most relevant for: Women with an inherited mutation linked to increased risk for cancer

Women with inherited mutations in genes that increase breast and ovarian cancer risk have an additional challenge: coping with how those mutations impact their families and how a family member’s cancer experience can shape their own perception. In a recent U.S. News and World Report article, Elaine Howley explores how a woman's decisions about healthcare, cancer prevention and treatment are affected by experience with cancer in the family. (9/25/18)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with BRCA1 mutations who have had risk-reducing ovary removal and have never been diagnosed with breast cancer

Does hormone therapy (HT) alter the risk of breast cancer for woman carrying a BRCA1 mutation who have never been diagnosed with cancer? In this study, researchers showed that among women with BRCA1 mutations, HT use did not increase breast cancer rates for 10 years after ovary removal. More women taking combined estrogen plus progesterone developed breast cancer compared to those taking estrogen only, though this difference was not statistically significant. (9/7/18)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Gardening improves health outcomes for breast cancer patients

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People diagnosed with breast cancer who would benefit from increased activity and from eating more vegetables

Research has shown that adopting a healthier lifestyle may improve overall health and outcomes for cancer survivors. This study looked at a 1-year home-based gardening intervention to increase activity and wellbeing among breast cancer survivors. (08/31/18)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Study identifies genes associated with risk of triple-negative breast cancer

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People diagnosed with triple-negative breast cancer

Panel testing can identify women who are at increased risk for breast cancer.  However, those at risk for triple-negative breast cancer cannot easily be identified because other than BRCA1, genes that increase the risk for triple-negative breast cancer are unknown.  A new study uses panel testing to identify which genes increase the risk for triple-negative breast cancer. (8/23/18)

Read More

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Declining use of chemotherapy for early-stage breast cancer: examining oncologist recommendations

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People diagnosed with early stage breast cancer

A new study shows that chemotherapy use for early-stage, node-positive and node-negative breast cancers declined from 2013 to 2015. It also reports that oncologists’ recommendations are influenced to differing degrees by patient preferences and tumor test results, despite unchanging health care guidelines. (8/21/18)

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Immunotherapy may lead to long-term remission of metastatic breast cancer

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with advanced cancers

Metastatic breast cancer is often difficult to treat. In a new approach, called adoptive cell therapy (ACT), a patient’s own T-cells (a type of cancer-fighting immune cells) are collected, multiplied in a lab, and then returned to the patient. The goal is to enhance the patient’s immune system with many more T-cells that recognize and attack metastasized tumor cells. This study reports on a single patient whose metastatic breast cancer is still in remission (no evidence of disease) after more than 22 months following ACT. (8/16/18)

Read More